Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer  by Galluzzi, Lorenzo et al.
Cell Reports
ArticlePrognostic Impact of Vitamin B6 Metabolism
in Lung Cancer
Lorenzo Galluzzi,1,2,3,40 Ilio Vitale,1,2,3,40 Laura Senovilla,1,2,3,40 Ken Andre´ Olaussen,2,3,4 Guillaume Pinna,5,6
Tobias Eisenberg,7 Aı¨cha Goubar,2,3,4 Isabelle Martins,1,2,3 Judith Michels,1,2,3 Gueorgui Kratassiouk,5,6
Didac Carmona-Gutierrez,7 Marie Scoazec,2,8 Erika Vacchelli,1,2,3 Frederic Schlemmer,1,2,3 Oliver Kepp,1,2,3
Shensi Shen,1,2,3 Maximilien Tailler,1,2,3 Mireia Niso-Santano,1,2,3 Eugenia Morselli,1,2,3 Alfredo Criollo,1,2,3
Sandy Adjemian,1,2,3 Mohamed Jemaa`,1,2,3 Kariman Chaba,2,9,14 Claire Pailleret,1,2,3 Mickae¨l Michaud,1,2,3
Federico Pietrocola,1,2,3 Nicolas Tajeddine,1,2,3 Thibault de La Motte Rouge,15 Natalia Araujo,5,6 Nadya Morozova,5,6
Thomas Robert,2,10 Hugues Ripoche,2,16 Frederic Commo,2,3,4 Benjamin Besse,2,11 Pierre Validire,17 Pierre Fouret,18,19,20
Ange´lique Robin,2,3,4 Nicolas Dorvault,2,3,4 Philippe Girard,21 Se´bastien Gouy,12 Patricia Pautier,11 Nora Ja¨gemann,22
Ann-Christin Nickel,23 Sabrina Marsili,24 Caroline Paccard,25,26,27 Nicolas Servant,25,26,27 Philippe Hupe´,25,26,27,28
Carmen Behrens,29 Parviz Behnam-Motlagh,30 Kimitoshi Kohno,31 Isabelle Cremer,32 Diane Damotte,33 Marco Alifano,34
Øivind Midttun,35 Per Magne Ueland,36 Vladimir Lazar,2,10 Philippe Dessen,2,10,18 Hans Zischka,22 Etienne Chatelut,24
Maria Castedo,1,2,3 Frank Madeo,7 Emmanuel Barillot,25,26,27 Juergen Thomale,23 Ignacio Ivan Wistuba,29
Catherine Saute`s-Fridman,32,37,38 Laurence Zitvogel,2,9,14 Jean-Charles Soria,2,3,4,13 Annick Harel-Bellan,5,6
and Guido Kroemer1,8,32,37,39,*
1INSERM, U848, F-94805 Villejuif, France
2Institut Gustave Roussy, F-94805 Villejuif, France
3Universite´ Paris-Sud XI, F-94805 Villejuif, France
4INSERM, U981, F-94805 Villejuif, France
5Universite´ Paris-Sud XI, PArI Platform, F-91191 Gif-sur-Yvette, France
6CNRS, FRE3377, F-91191 Gif-sur-Yvette, France
7Institute of Molecular Biosciences, University of Graz, A-8010 Graz, Austria
8Metabolomics Platform
9Center of Clinical Investigations in Biotherapies of Cancer (CICBT 507)
10Unite´ de Ge´nomique Fonctionnelle et Bioinformatique
11Department of Medical Oncology
12Department of Surgery
13SITEP (Phase I Unit)
Institut Gustave Roussy, F-94805 Villejuif, France
14INSERM, U1015, F-94805 Villejuif, France
15Service d’Oncologie Me´dicale, Groupe Hospitalier Pitie´-Salpeˆtrie`re, F-75651 Paris, France
16CNRS, UMR8200, F-94805 Villejuif, France
17Service d’Anatomie Pathologique, Institut Mutualiste Montsouris, F-75014 Paris, France
18INSERM, U985, F-94805 Villejuif, France
19Service d’Anatomie Pathologique, Groupe Hospitalier Pitie´-Salpeˆtrie`re, F-75651 Paris, France
20Universite´ Pierre et Marie Curie VI, F-75005 Paris, France
21De´partement Thoracique, Institut Mutualiste Montsouris, F-75014 Paris, France
22Institute of Toxicology, Helmholtz Center Munich, German Research Center for Environmental Health, D-85764 Neuherberg, Germany
23Institute for Cell Biology (Cancer Research), University of Duisburg-Essen Medical School, D-45122 Essen, Germany
24EA4553 Institut Claudius-Regaud, F-31052 Toulouse, France
25Institut Curie, F-75248 Paris, France
26INSERM, U900, F-75248 Paris, France
27Mines ParisTech, F-77300 Fontainebleau, France
28CNRS, UMR144, F-75248 Paris, France
29The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
30Department of Medical Biosciences, Umea˚ University, SE-901 87 Umea˚, Sweden
31Department of Molecular Biology, School of Medicine, University of Occupational and Environmental Health, 807-8555 Kitakyushu, Japan
32Centre de Recherche des Cordeliers, F-75006 Paris, France
33Pathology Departement, Universite´ Paris Descartes V, F-75270 Paris, France
34Thoracic Surgery Department, Hoˆtel Dieu, APHP, F-75004 Paris, France
35Bevital AS, N-5021 Bergen, Norway
36Section for Pharmacology, Institute of Medicine, University of Bergen, N-5021 Bergen, Norway
37Universite´ Paris Descartes V, F-75270 Paris, France
38INSERM, U872, F-75006 Paris, France
39Poˆle de Biologie, Hoˆpital Europe´en Georges Pompidou, AP-HP, F-75908 Paris, France
40These authors contributed equally to this work
*Correspondence: kroemer@orange.fr
http://dx.doi.org/10.1016/j.celrep.2012.06.017Cell Reports 2, 257–269, August 30, 2012 ª2012 The Authors 257
SUMMARY
Patients with non-small cell lung cancer (NSCLC) are
routinely treated with cytotoxic agents such as
cisplatin. Through a genome-wide siRNA-based
screen, we identified vitamin B6 metabolism as
a central regulator of cisplatin responses in vitro
and in vivo. By aggravating a bioenergetic catas-
trophe that involves the depletion of intracellular
glutathione, vitamin B6 exacerbates cisplatin-medi-
ated DNA damage, thus sensitizing a large panel of
cancer cell lines to apoptosis. Moreover, vitamin B6
sensitizes cancer cells to apoptosis induction by
distinct types of physical and chemical stress,
including multiple chemotherapeutics. This effect
requires pyridoxal kinase (PDXK), the enzyme that
generates the bioactive form of vitamin B6. In line
with a general role of vitamin B6 in stress responses,
low PDXK expression levels were found to be associ-
ated with poor disease outcome in two independent
cohorts of patients with NSCLC. These results indi-
cate that PDXK expression levels constitute a
biomarker for risk stratification among patients with
NSCLC.
INTRODUCTION
During the past two decades, major efforts have been dedicated
to the mechanistic exploration of biochemical and metabolic
features that constitute common denominators of neoplasia,
irrespective of its histologic origin. According to the milestone
conceptualization by Hanahan and Weinberg, such hallmarks
of cancer include an elevated resistance to the induction of cell
death (Hanahan and Weinberg, 2000, 2011). Thus, cancer cells
fail to die in response to signals that would lead to the demise
of normal cells, a feature that sustains early oncogenesis
(when cancer cells become able to tolerate the stress caused
by oncogene activation), tumor progression (when cancer cells
endure harsh environmental conditions, such as those encoun-
tered within poorly vascularized tumor nodules) and resistance
to radiation therapy and chemotherapy (which, in principle, aim
at activating cell-intrinsic pathways to cell death) (Hanahan and
Weinberg, 2000, 2011).
Cell death resistance can result from the inactivation/downre-
gulation of positive modulators of apoptosis, like TP53 and ARF
(Brown et al., 2009; Gil and Peters, 2006), or the hyperactivation/
overexpression of anti-apoptotic factors such as BCL-2-like and
inhibitor of apoptosis proteins (Gyrd-Hansen and Meier, 2010;
Youle and Strasser, 2008). Moreover, malignant cells can
acquire resistance to otherwise lethal conditions in the context
of (and sometimes due to) an extensive rewiring of metabolic
circuitries (Kroemer and Pouyssegur, 2008; Ward and Thomp-
son, 2012). For instance, the pentose phosphate pathway is
often hyperactivated in cancer cells, supplying them with
anabolic substrates as well as with reducing equivalents that
can be used to counteract oxidative stress (Anastasiou et al.,258 Cell Reports 2, 257–269, August 30, 2012 ª2012 The Authors2011). Accumulating evidence indicates that the molecular
cascades that regulate cell death and metabolism are exten-
sively intertwined (Buchakjian and Kornbluth, 2010; Vousden
and Ryan, 2009). Thus, one of the major checkpoints of cell
death regulation, i.e., mitochondrial membrane permeabiliza-
tion, is profoundly influenced by bioenergetic metabolism (Ala-
vian et al., 2011; Kroemer et al., 2007), and the expression profile
of pro-apoptotic BH3-only proteins as well as metabolic
biomarkers have been shown to predict the fate of patients
with cancer (Lodi and Ronen, 2011; Ni Chonghaile et al., 2011).
Paradoxically, current anticancer therapies aim at killing
malignant cells that, in the majority of cases, are intrinsically
resistant to the induction of cell death, at least to some extent.
Even when an initial pyrrhic response to therapy can be attained,
leading to a transient reduction in the tumor burden, the
Darwinian selection of chemoresistant clones often determines
chemotherapeutic failure (Se`ve and Dumontet, 2005). As
a standalone example, non-small cell lung cancer (NSCLC),
one of the leading causes of cancer-related death among males
(Jemal et al., 2008), is frequently treated with platinum deriva-
tives such as cisplatin (cis-diammineplatinum(II) dichloride,
CDDP), yielding highly heterogeneous and, in the best-case
scenario, transitory responses (Cosaert and Quoix, 2002).
On the basis of these premises and incognita, we decided to
launch a genome-wide siRNA screen to identify novel proteins
that affect the response of NSCLC to CDDP. Here, we report
85 newly identified CDDP response modifiers (CRMs), including
pyridoxal kinase (PDXK), the enzyme that generates the biolog-
ically active form of vitamin B6. Furthermore, we demonstrate
that the vitamin B6 precursor pyridoxine (PN) exacerbates, in
a PDXK-dependent fashion, CDDP cytotoxicity in vitro and
in vivo, as well as the response of cancer cells to CDDP-unre-
lated stress conditions. Finally, we show that the expression
levels of PDXK influence the fate of patients with cancer, sug-
gesting that PDXK may constitute a novel prognostic biomarker
for risk stratification.
RESULTS
Genome-wide siRNA Screen for the Identification
of CRMs
To identify novel factors involved in the cellular response to
CDDP, we transfected human NSCLC A549 cells with a panel
of small interfering RNAs covering the entire genome (two
siRNAs targeting a total of 23,078 gene products) and then
exposed them to 50 mM CDDP for 24 hr. These conditions
were selected as they led to the death of 50% of cells that
had been transfected with a control siRNA. At the end of the
assay, cytotoxicity and cell number were estimated by
measuring the release of lactate dehydrogenase (LDH) into the
cell supernatant and the conversion of a tetrazolium salt
(WST-1), respectively. At this stage, 12.6% of all siRNAs were
excluded from further analyses, as they exerted per se (in the
absence of CDDP) cytotoxic or antiproliferative effects.
Conversely, gene products for which both siRNAs modulated
the cellular response to CDDP in a concordant fashion (i.e.,
they both reduced or they both exacerbated CDDP cytotoxicity)
were ranked based on their biological potency, and the top 1,000
ones were subjected to a first round of validation. This round,
which entailed two additional siRNAs per gene product, allowed
us to identify 85 gene products whose downregulation by at least
three out of four non-overlapping siRNAs concordantly modu-
lated the response of A549 cells to CDDP (Figure 1A and Table
S1). Fifty-three of these hits were ‘‘cytoprotectors’’ (their deple-
tion enhanced CDDP cytotoxicity) while 32 were ‘‘chemosensi-
tizers’’ (their knockdown inhibited CDDP cytotoxicity), and at
least 34 among them (24 cytoprotectors and eight chemosensi-
tizers) were ‘‘druggable’’ (at least in vitro) according to the
current knowledge (Figure S1A). Chemosensitizers included
the anaplastic lymphoma kinase (ALK), a receptor tyrosine
kinase that is frequently involved in oncogenic fusion proteins
(i.e., NPM-ALK) (Morris et al., 1994). While previous reports indi-
cate that wild-type ALK is not expressed by NSCLC cells (Iwa-
hara et al., 1997; Morris et al., 1994; Rikova et al., 2007; Stoica
et al., 2002), we validated our finding by immunoblotting, upon
transfection of A549 cells with a control siRNA or with two,
nonoverlapping siRNAs targeting ALK (data not shown).
To validate the screening results, A549 cells were subjected to
the siRNA-mediated knockdown of selected druggable hits and
then exposed to sub-apoptotic (25 mM) or highly cytotoxic
(75 mM) doses of CDDP (which are best suited to highlight che-
mosensitization and cytoprotection, respectively) for 48 hr, and
then assayed by cytofluorometry for cell death-related parame-
ters (i.e., dissipation of the mitochondrial transmembrane poten-
tial and plasma membrane breakdown) (Figures S1B and S1C
and Table S2). As a complementary validation, cells were incu-
bated with CDDP alone or in the presence of specific pharmaco-
logic inhibitors of druggable hits (Figure S1D). In line with the
results of the primary screen, both the depletion and inhibition
of ZDHHC9 (a palmitoyl transferase of H-RAS and N-RAS), inter-
leukin 6 (IL6) or its receptor (IL6R), BCL2L1 (better known as
BCL-XL), and RAC2 (a small GTP-binding protein) sensitized
A549 cells to CDDP-induced cell death, while the depletion/inhi-
bition of two distinct cytochrome c oxidase (COX) subunits and
that of apoptotic peptidase activating factor 1 (APAF1) exerted
cytoprotective effects (Figures S1B–S1D). Thus, our screen
identified known modulators of apoptosis (such as BCL-XL and
APAF1) as well as proteins that had never been implicated in
CDDP-elicited signaling pathways.
Identification of General Cell Death Modulators versus
CRMs
To discriminate between general regulators of cell death and
specific CRMs, we assessed our 85 hits (1) for their capacity to
modulate CDDP cytotoxicity in six distinct CDDP-resistant
A549 clones, four additional NSCLC cell lines, four ovarian carci-
noma cell lines, and wild-type or TP53/ HCT 116 colon cancer
cells (Figure 1A); and (2) for their capacity to influence the
response of A549 cells to 13 different cytotoxic agents including
three platinum compounds (CDDP, carboplatin, and oxaliplatin),
six platinum-unrelated anticancer drugs (betulinic acid, campto-
thecin, doxorubicin, etoposide, mitoxantrone, and mytomicin c),
and four cellular toxins (ceramide, cadmium, staurosporine, and
thapsigargin) (Figure 1B). Unsupervised hierarchical clustering of
these data sets revealed the existence of response patterns that
were similar in cancer cells of the same type (for instance, allNSCLC cell lines or ovarian cell lines but TOV-112D) as well as
of cell line-specific profiles (such as that of TOV-112D cells) (Fig-
ure 1A and Table S3). This method also uncovered the existence
of general (e.g., COX5B, PSMD7, TRIP4) and agent-specific
(e.g., ALK, CLIC1, IL6R, etc.) modulators of the cell death
response (Figure 1B and Table S4). Moreover, we found that
the depletion of the 85 hits identified in our screen induced rela-
tively similar modifications in the response of A549 cells to CDDP
and carboplatin, yet rather dissimilar changes when CDDP and
oxaliplatin were compared (Figure 1B and Table S4). This reflects
previously reported differences in the mechanisms of action of
these platinum-based chemotherapeutics (Galluzzi et al., 2010;
Tesniere et al., 2010).
Combinatorial Screening of CRMs
To gain further insights into the functional connections among
the CRMs identified in our screen, we performed a systematic
combinatorial analysis. To this aim, we used siRNAs for the
depletion of each of our 85 hits as well as of seven additional
proteins that we and others had identified as CRMs (BAK1,
BAX, BCL2, CASP2, STAT3, TP53, VDAC1) (Castedo et al.,
2006; de La Motte Rouge et al., 2007; Seth et al., 2005; Tajed-
dine et al., 2008). A549 cells were transfected in triplicate
instances with 92 3 92 couples of siRNAs (a total of 25,392
test conditions, controls excluded), treated with CDDP as in
the original screen, and assayed for WST-1 conversion. The
resultant matrix of combinatorial effects (Figure 2) was sub-
jected to unsupervised hierarchical clustering (following the
Ward method and the Pearson correlation), leading to the iden-
tification of four separate clusters of functionally noninteracting
gene products (Table S5).
Thus, the simultaneous knockdown of hits belonging to the
same cluster failed to yield any functional interaction (i.e., the
effects of the codepletion were equal to the effects of the deple-
tion of either these two hits alone). Conversely, the concomitant
knockdown of hits belonging to distinct clusters caused at least
additive effects. Some of these results were expected (such as
the classification of the anti-apoptotic proteins BCL2, BCL-XL,
and MCL1 together in cluster 1, that of the COX subunits Vb
and VIId together in cluster 3, and that of the pro-apoptotic
proteins BAX, BAK1, APAF1, TP53, VDAC1, CASP2, the BCL2
interactor NLRP1, and two proteasome subunits together in
cluster 4), while others were not (such as the presence of IL6R,
STAT3, and CLIC1 in cluster 1). This approach was validated
by using siRNAs (Figures S2A–S2C), pharmacologic inhibitors
(Figures S2D–S2F) and cytofluorometry as an alternative
readout. The combined depletion/inhibition of ZDHHC9 (which
is targeted by 2-bromopalmitate) and IL6R (which can be
blockedby anextracellular antibody), both belonging to cluster 1,
provided no additional chemosensitization as compared to
depletion/inhibition of either these factors alone (Figures S2A
and S2D). In contrast, the concomitant knockdown/inhibition of
IL6R (in cluster 1) and RAC2 (which can be inhibited by EHT
1864 and belonged to cluster 2) sensitized to CDDP cytotoxicity
more than the depletion/inhibition of IL6R or RAC2 alone (Figures
S2B and S2E). Along similar lines, the simultaneous downregula-
tion of COX (in cluster 3) and TP53 (in cluster 4) yielded an addi-
tional protection against CDDP as compared to the depletion ofCell Reports 2, 257–269, August 30, 2012 ª2012 The Authors 259
Figure 1. Functional Characterization of CRMs inMultiple Cancer Cell Lines and in A549Cells Challengedwith CDDP-Related and -Unrelated
Cell Death Inducers
(A) Unsupervised hierarchical clustering of the effects of the 85 hits from the siRNA screen on the response to cisplatin (CDDP) of WT human NSCLC A549 cells,
six distinct CDDP-resistant A549 clones (A549 no. 1–6), four NSCLC cell lines other than A549 (i.e., HCC827, H1299, H1650, and H1975 cells), four ovarian cancer
cell lines (i.e., A2780, HEY, OV2008, and TOV-112D cells) as well as WT and TP53/ colon carcinoma HCT 116 cells. Green and red boxes depict
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Figure 2. Clustering of the Interactions between CRMs
Clustering of the effects of the co-transfection of each of the 85 hits from the secondary screen (plus 7 control siRNAs) with each other on the response of A549
cells to cisplatin (CDDP). For each couple of siRNAs, colored boxes depict the degree of mutual interaction, ε (varying from 1 to + 1). ε = 0 represents the
absence of interaction, ε < 0 an alleviating interaction (the effects of the cotransfection are lower than the sum of the effects of each siRNA transfected alone), and
ε > 0 an aggravating interaction (the effects of the cotransfection are higher than the sum of the effects of each siRNA transfected alone). This analysis allows for
the identification of four clusters of CDDP response modifiers (CRMs). See also Supplemental Information, Figure S2 and ,Tables S2 and S5.either these proteins alone (Figure S2C). Similar results were ob-
tained by inhibiting COX and TP53 with sodium azide and cyclic
pifithrin a, respectively (Figure S2F). Altogether, these observa-
tions suggest that (at least) four different signaling modules
determine CDDP responses.siRNA-mediated chemosensitization (D < 0) and cytoprotection (D > 0), respect
administration of CDDP) in siRNA-transfected cells and the residual proliferation
(B) Unsupervised hierarchical clustering of the effects of the 85 hits from the siRN
C2-ceramide, cadmium chloride, camptothecin, carboplatin, doxorubicin, etopos
Green and red boxes depict siRNA-mediated chemosensitization (D < 0) and cytop
proliferation (upon the administration of the indicated drug) in siRNA-transfecte
(siUNR). See also Supplemental Information, Figure S1, and Tables S1, S2, S3, aImpact of Intermediate Metabolism on CDDP
Responses, In Vitro and In Vivo
Among the 85 CRMs uncovered by our screen, we were partic-
ularly interested in pyridoxal kinase (PDXK), the enzyme that
converts vitamin B6 precursors into their bioactive derivative,ively. D represents the difference between the residual proliferation (upon the
in cells transfected with a control siRNA (siUNR).
A screen on the response of human NSCLC A549 cells to CDDP, betulinic acid,
ide, mitoxantrone, mytomycin C, oxaliplatin, staurosporine, and thapsigargin.
rotection (D > 0), respectively.D represents the difference between the residual
d cells and the residual proliferation in cells transfected with a control siRNA
nd S4.
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Figure 3. Influence of Vitamin B6 Metabolism on the Response to CDDP of Cancer Cells In Vitro and In Vivo
(A) Schematic representation of vitamin B6 metabolism in humans. PDXK, pyridoxal kinase; PDXP, pyridoxal phosphatase; PNPO, pyridoxamine 50-phosphate
oxidase; PL, pyridoxal; PLP, pyridoxal-5-phosphate; PM, pyridoxamine; PMP, pyridoxamine-50-phosphate; PN, pyridoxine; PNP, pyridoxine-50-phosphate.
(B) Quantification of intracellular B6 vitamers (PLP + PN + PM + PL) upon acute administration of PLP, PM or PN to A549 cells for 24 or 48 hr. ** = p < 0.001
(Student’s t test), as compared to PBS-treated cells.
(C) Cytofluorometric assessment of cell death induced by 25 mM cisplatin (CDDP) in A549 cells co-treated with the indicated B6 vitamers for 48 hr. PI+ = dead
cells; PI- DiOC6(3)
low = dying cells. Mean±SEM (n = 3). * = p < 0.05 (Student’s t test), as compared to untreated cells. # = p < 0.05 (Student’s t test), as compared to
cells treated with the same concentration of CDDP. See also Figures S3A–S3C and S4.
(D and E) Cytofluorometric assessment of cell death induced by 25 or 75 mM CDDP in A549 cells transfected with siRNAs targeting the indicated vitamin B6-
relevant enzymes. PI+ = dead cells; PI- DiOC6(3)
low = dying cells. Mean ± SEM (n = 3). * = p < 0.05 (Student’s t test), as compared to untreated siUNR-transfected
cells. # = p < 0.05 (Student’s t test), as compared to siUNR-transfected cells treated with the same concentration of CDDP. See also Figures S3D and S3E.
(F) Combined effects of PDXK depletion and PN administration on CDDP-induced cell death. PI+ = dead cells; PI- DiOC6(3)
low = dying cells. Mean ± SEM (n = 3).
* = p < 0.05 (Student’s t test), as compared to untreated siUNR-transfected cells. # = p < 0.05 (Student’s t test), as compared to siUNR-transfected cells treated
with CDDP only. n.s. = non-significant (Student’s t test), as compared to siPDXK-transfected cells treated with CDDP only. See also Figure S3D.
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pyridoxal-5-phosphate (PLP) (Figure 3A) (Lee et al., 2000), for
two reasons. First, the knockdown of PDXK protected all tested
cell lines against CDDP cytotoxicity (Figure 1A), and A549 cells
against a plethora of cytotoxic agents (Figure 1B), thus far dis-
playing the widest cytoprotective potential in our models.
Second, recent results from a large population study demon-
strate a negative correlation between vitamin B6 serum levels
and the risk of developing NSCLC (Johansson et al., 2010).
Thus, we decided to investigate the effect of the bioactive form
of vitamin B6 (PLP) and its main precursor pyridoxine (PN) on
CDDP responses.
The acute administration of PN (but neither that of PLP, which
cannot cross the plasma membrane of most mammalian cells,
nor that of pyridoxamine) increased the intracellular concentra-
tion of B6 vitamers (Figure 3B) and aggravated CDDP cyto-
toxicity, as quantified by cytofluorometry (Figure 3C) or by
measuring the impedance of viable cells growing on microelec-
trode-coated plates (Figure S3A). Along similar lines, the contin-
uative presence of higher-than-normal or lower-than-normal
amounts of B6 vitamers in the culture medium exacerbated or
inhibited, respectively, the response of A549 cells to CDDP
(Figure S3B). Moreover, PN aggravated the loss of clonogenic
potential triggered in Saccharomyces cerevisiae cells by a brief
exposure to high doses of CDDP, an effect that was even more
pronounced for PLP (Figure S3C). Indeed, PLP is readily taken
up by yeast, as demonstrated by the fact that S. cerevisiae cells
lacking the vitamin B6-related gene snz1 do not grow in vitamin
B6-deficient medium, while they do so upon the addition of PLP
(data not shown). Next, we transfected A549 cells with siRNAs
targeting PDXK and pyridoxal phosphatase (PDXP), the enzyme
that functionally antagonizes PDXK (Figure 3A), and tested their
response to CDDP. As expected, PDXK depletion reduced
CDDP-induced cell death, while the knockdown of PDXP exac-
erbated it (Figures 3D, 3E, and S3D). The effects of PN were
lost upon PDXK depletion, in line with the notion that PN
must be converted into PLP to become biologically active
(Figure 3F). In yeast, the knockout of two vitamin B6-related
genes, sno1 and snz1, prevented CDDP-induced cell death
(Figure S3E).
Systemic injections of PN improved the antitumor effects of
CDDP-based chemotherapy in vivo, in murine Lewis lung carci-
noma cells transplanted into syngenic C57BL/6 mice, in both
models of induction (tumors treated when palpable) and regres-
sion (tumors treated when volume reached 1 cm3) (Figures 3G
and 3H). The same held true for human NSCLC H460 cells
growing in immunodeficient animals (Figure 3I). In vitro, PN exac-
erbated CDDP cytotoxicity in 8 additional NSCLC cell lines
(besides A549 cells), 4 ovarian carcinoma cell lines, cervical
carcinoma, osteosarcoma, mesothelioma and wild-type (but
not TP53/) colorectal cancer cells, murine lung carcinoma
cells, as well as in multiple distinct CDDP-resistant cell lines(G–I) In vivo growth of murine LLC (G and H) or human NSCLC H460 (I) cells grafte
mice upon treatment (initiated as indicated) with intraperitoneal CDDP alone or in
ANOVA), as compared to PBS-treated mice. # = p < 0.05 (two-way ANOVA), as
(J and K) PDXK and PDXP expression in isogenic CDDP-sensitive (S) and CDDP
were monitored to ensure equal loading of lanes. Quantitative data upon normaliz
0.001, (Student’s t test), as compared to S cells of the same type.(Figure S4), underscoring the general impact of vitamin B6
metabolism on CDDP responses. Of note, four distinct types of
CDDP-resistant cells (as obtained by continuous selection in
CDDP-containing medium) exhibited decreased PDXK/PDXP
ratio (due to decreased PDXK or increased PDXP protein levels)
as compared to their CDDP-sensitive counterparts (Figures 3J
and 3K).
Mechanism of Vitamin B6-Mediated
Chemosensitization and General Impact of Vitamin B6
Metabolism in Stress Responses
In line with previous reports (Previati et al., 2006), both non-
oxidized glutathione (GSH) and N-acetylcysteine (NAC) fully pre-
vented apoptosis induction by CDDP (irrespective of the
presence of PN) (Figure 4A). Conversely, inhibition of caspases
reduced the cytotoxicity of CDDP (alone or in combination with
PN), yet it did not completely abrogate PN-mediated chemosen-
sitization (Figure 4A). In the presence of PN, cells treated by
a sub-apoptotic concentration of CDDP exhibited increased
phosphorylation of TP53 on serines 15 and 46, and increased
activation of caspase-3 and -9 (Figure 4B). Moreover, PN signif-
icantly increasedCDDP-DNA adducts, as quantified by immuno-
fluorescence staining of cells cultured in the presence of CDDP
(Figure 4C) followed by automated image analysis (Figure 4D).
Accordingly, two signs of an ongoing DNA damage response
to CDDP, namely the activating phosphorylation (on Ser 1981)
of the ataxia telangiectasia mutated (ATM) kinase and the phos-
phorylation on Ser 136 of the ATM substrate histone 2AX (H2AX),
were aggravated in the presence of PN (Figures 4E–4H). The
accumulation of CDDP-DNA adducts as well as the activation
of ATM and H2AX were prevented by the presence of NAC in
the culture medium. Taken together, these results suggest that
PN exacerbates the cytotoxic effects of CDDP (which are medi-
ated by both caspase-dependent and -independent pathways)
upstream of the DNA damage response and by a mechanism
that can be blocked by antioxidants.
To get further insights into the molecular circuitries underlying
vitamin B6-mediated chemosensitization, we performed tar-
geted metabolomic determinations and metabolomic profiling.
We found that, in pre-apoptotic conditions, NSCLC cells treated
with CDDP and PN exhibited a bioenergetic defect (measured in
terms of Atkinson’s energy charge = [ATP] + 0.5 [ADP] / [ATP] +
[ADP] + [AMP]) (Atkinson, 1968) that was not present in cells
incubated with either these compounds alone (Figure 5A and
Figures S5A–S5C). Moreover, A549 cells succumbed to CDDP
while manifesting a decrease in the intracellular levels of GSH
(Figures 5B and 5C) as well as of three metabolites with molec-
ular weights of approximately 161, 203, and 217 Da, which
were identified as carnitine, acetyl-carnitine, and propionyl-
carnitine, respectively (Figures S5D–S5F). Such a decrease in
GSH and redox-relevant metabolites was largely aggravatedd into immunocompetent C57BL/6 (G and H) or immunodeficient Swiss nude (I)
combination with PN. Mean ± SEM (10–20 mice/group). * = p < 0.05 (two-way
compared to mice treated with CDDP only.
-resistant (R) cancer cell lines. Representative immunoblots (J). GAPDH levels
ation to S cells of the same type (K). Mean ± SEM (n = 2-3). * = p < 0.05, ** = p <
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Figure 4. Mechanisms of Chemosensitiza-
tion by PN In Vitro
(A) Cytofluorometric quantification of A549 cell
death induced by 25 or 75 mM cisplatin (CDDP)
alone or in combination with pyridoxine (PN) and/
or reduced glutathione (GSH), N-acetylcysteine
(NAC) and the pan-caspase inhibitor Z-VAD.fmk.
PI+ = dead cells; PI- DiOC6(3)
low = dying cells.
Mean ± SEM (n = 3). * = p < 0.05 (Student’s t test),
as compared to untreated cells. # = p < 0.05
(Student’s t test), as compared to cells treated
with the same concentration of CDDP. x = p < 0.05
(Student’s t test), as compared to cells treated
with the same concentration of CDDP and PN. ^=
p < 0.05 (Student’s t test), as compared to cells
treated with the same concentration of CDDP and
Z-VAD.fmk.
(B) Immunoblotting-based assessment of the
activation of the intrinsic apoptosis pathway in
A549 cells treated with 25 mM CDDP alone or in
combination with PN. CASP, caspase. GAPDH
levels were monitored to ensure equal loading.
(C–H) DNA damage response in A549 cells chal-
lenged with 25 mM CDDP alone or combined with
PN and/or NAC. Representative immunofluores-
cence microphotographs of CDDP-DNA adducts
(C), the activating phosphorylation of ATM
(P-ATM) (E) and the phosphorylation of histone
2AX (g-H2AX) (F) in untreated versus CDDP-
treated cells. White bars indicate picture scale
(C, E, and F). Kinetic data as obtained upon
automatic image analysis of fluorescence (D) or
visual quantification of the % of cells exhibiting
more than 5 (G) or 10 (H) bright nuclear spots (DNA
damage foci). Untreated cells exhibit no CDDP-
DNA adducts and baseline (<5% positive cells)
activation of the DNA damage response (not
shown). Mean ± SEM (n = 3). * = p < 0.05
(Student’s t test), as compared to untreated cells.
# = p < 0.05 (Student’s t test), as compared to cells
treated with CDDP only (D, G, and H).by PN (Figures 5B, 5C and S5D–S5F). Still, only GSH (Figure 4A)
(but not carnitine metabolites, Figures S5G and S5H) could
protect cells against the cytotoxic effect of CDDP plus PN. These
results indicate that vitamin B6 exerts chemosensitizing effects
by interfering in a multipronged fashion with the redox
metabolism.
We therefore hypothesized that the vitamin B6 metabolism
might have a general impact on the cellular management of
stress. Indeed, PN rendered A549 cells more sensitive to hyper-
thermia, ionizing irradiation, hypoxia, respiratory chain inhibition
(with high doses of KCN), and nutrient depletion (Figure 5D). As in
the case of CDDP (Figure 3F), PN-mediated sensitization was
abrogated by the siRNA-mediated knockdown of PDXK (Figures
5D and S3D).264 Cell Reports 2, 257–269, August 30, 2012 ª2012 The AuthorsPrognostic Value of PDXK inNSCLC
Given the profound implication of vitamin
B6 and PDXK in the response of NSCLC
to CDDP as well as in the management
of cellular stress, we wanted to investi-gate the influence of PDXK expression levels in the clinical
setting. To this aim, we developed an immunohistochemical
staining method that specifically detects PDXK (as demon-
strated by the fact that siRNA-mediated depletion of PDXK
results in the complete loss of the signal) (Figures S6A and
S6B) and applied it to specimens from a first NSCLC patient
cohort. These patients were affected by localized NSCLC and
underwent surgery followedbyoptional adjuvantCDDP (Table 1).
Upon immunohistochemical analysis (Figure 6A), samples were
divided into two groups with high (>median) and low (<median)
PDXK expression. High PDXK expression levels had a significant
positive impact on both disease-free and overall survival (Fig-
ure 6B), independent on whether patients did or did not receive
adjuvant chemotherapy (not shown). A similar positive impact of
Figure 5. Bioenergetic Aspects of PN-Mediated Chemosensitization and Impact of Vitamin B6 Metabolism in Stress-Induced Cell Death
(A) Atkinson’s energy charge of A549 cells treated for 24 hr with 25 mM cisplatin (CDDP) and pyridoxine (PN), alone or in combination. Mean ± SEM (n = 6). * = p <
0.05 and n.s. = non-significant (Student’s t test), as compared to untreated cells. # = p < 0.05 (Student’s t test), as compared to cells treated with CDDP only. x =
p < 0.05 (Student’s t test), as compared to cells treated with PN only. See also Figures S5A–S5C.
(B) Cytofluorometric assessment of intracellular GSH levels in A549 cells treated for 24 hr with the indicated concentration of CDDP, alone or in combination with
PN. Columns report the% of cells with low intracellular GSH (MCBlow). Mean ± SEM (n = 6). * = p < 0.05 (Student’s t test), as compared to untreated cells. # = p <
0.05 (Student’s t test), as compared to cells treatedwith the same concentration of CDDP only. x = p < 0.05 (Student’s t test), as compared to cells treatedwith the
same concentration of CDDP plus PN. Mean ± SEM (n = 6). See also Figures S5D–S5H.
(C) Intracellular levels of GSH, asmeasured bymass spectrometry, in A549 cells treated for 24 hr with 25 mMCDDP and PN, alone or in combination. Mean ± SEM
(n = 6). * = p < 0.05 and n.s. = non-significant (Student’s t test), as compared to untreated cells. # = p < 0.05 (Student’s t test), as compared to cells treated with
CDDP only. x = p < 0.05 (Student’s t test), as compared to cells treated with PN only. See also Figures S5D–S5H.
(D) Combined effects of PDXK depletion and pyridoxine (PN) administration on stress-induced cell death. PI+ = dead cells; PI- DiOC6(3)
low = dying cells. Mean ±
SEM (n = 3). * = p < 0.05 (Student’s t test), as compared to untreated siUNR-transfected cells. # = p < 0.05 (Student’s t test), as compared to siUNR-transfected
cells treated with the same stress inducer. n.s. = non-significant (Student’s t test), as compared to siPDXK-transfected cells treated with the same stress inducer.
See also Figure S3D.high PDXK expression was found in a second cohort of patients
with NSCLC who underwent surgery without adjuvant chemo-
therapy (Table 1; Figure 6C).
There was no inter-individual correlation between PDXK
expression in neoplastic lesions and in adjacent normal tissues.
However, PDXK protein levels were higher in tumor cells than in
their normal counterparts (Figures S6C and S6D). The protein
levels of PDXK in the tumor, as quantified by immunohistochem-
istry and software-assisted image analysis, did not correlate with
the amounts of PDXKmRNA, as determined by gene expression
profiling (Figure S6E). This suggests that PDXK expression is
subjected to a consistent degree of post-translational control.
PDXP protein levels had no impact on the survival of patients
with NSCLC, and the same held true for other hits from our
screen, including ALDH7A1, ALK, BCL-XL, and WSB2, as deter-mined by systematic immunohistochemistry (Figures S7A–S7C).
Altogether, these results demonstrate that PDXK expression
levels constitute a biomarker for risk stratification among
patients with NSCLC.
DISCUSSION
In this work, we undertook a near-to-saturating genome-wide
siRNA screen to identify novel modulators of the cellular
response to CDDP. Driven by the characteristics of the siRNA
library that we employed (including four siRNAs per gene
product that were predicted, but not guaranteed, to function),
we deliberately chose to minimize false-negative results, at
the cost of missing potential interesting candidates. Still, this
approach and multiple rounds of validation allowed us toCell Reports 2, 257–269, August 30, 2012 ª2012 The Authors 265
Table 1. Patient Characteristics
Patients with NSCLC: Institut Mutualiste Montsouris (Paris, France)
Age (years)b 63 (41–85)
Follow-up (years)b,c 4.72
Adjuvant chemotherapya
No 55 (48.3)
Yes 59 (51.7)
Histologya
ADC 53 (46.5)
SCC 47 (41.2)
Other 14 (12.3)
Stagea
I 50 (47.2)
II 25 (23.6)
III 31 (29.2)
Sexa
F 32 (28.1)
M 82 (71.9)
Smoking statusa
Current 44 (38.9)
Former 62 (54.9)
Never 7 (6.2)
Patients with NSCLC: MD Anderson Cancer Center (Houston,
TX, USA)
Age (years)b 67 (41–90)
Follow-up (years)b 6.27
Adjuvant chemotherapya
No 218 (100)
Yes 0 (0)
Histologya
ADC 143 (65.6)
SCC 75 (34.4)
Stagea
I 165 (75.7)
II 41 (18.8)
III 12 (5.5)
Sexa
F 118 (54.1)
M 100 (45.9)
Smoking statusa
Current 87 (39.9)
Former 103 (47.3)
Never 28 (12.8)
See also Figures S6 and S7.
ADC, adenocarcinoma; NSCLC, non-small cell lung cancer; SCC,
squamous cell carcinoma.
aAbsolute number (percentage).
bMedian (range).
cDFS data were available for 111 patients, PDXKmRNA expression data
for 109 patients.
266 Cell Reports 2, 257–269, August 30, 2012 ª2012 The Authorsidentify 85 CRMs, encompassing known apoptosis regulators
(negative: MCL1, BCL2L1, TFF1; positive: APAF1) (Bossen-
meyer-Pourie´ et al., 2002; Kroemer et al., 2007), pro-survival
proteins (IL6R), as well as multiple proteins involved in interme-
diate metabolism (homogentisate 1,2-dioxygenase, HGD; high
density lipoprotein binding protein, HDLBP; fructosamine-3-
kinase-related protein, FN3KRP; COX subunits). The majority
of our 85 hits had cytoprotective properties, meaning that
their knockdown or their pharmacologic inhibition enhanced
CDDP-induced killing. On theoretical grounds, these cytopro-
tective proteins may constitute novel targets for chemosensiti-
zation. Combinatorial analyses suggest that dual interventions
on at least two among these gene products may have syner-
gistic effects. Such single- or dual-hit synthetic lethal effects
require further exploration as well as biological and pharmaco-
logical validation.
The knockdown of PDXK consistently reduced the cytotoxic
activity of CDDP. In line with these observations, we found that
the exogenous administration of PN (a cell-permeable B6 vi-
tamer) sensitized NSCLC cells to CDDP (in vitro and in vivo).
PN-mediated sensitization relied on the presence of PDXK,
occurred independently of caspases, and correlated with
a bioenergetic and redox catastrophe featuring an abrupt
decrease in the intracellular levels of reduced glutathione.
Importantly, we found that PN aggravates, in a PDXK-depen-
dent fashion, the lethal response of cancer cells to a wide range
of chemotherapeutics as well as to chemotherapy-unrelated
stress conditions, including hyperthermia, ionizing irradiation,
hypoxia, respiratory chain inhibition, and nutrient depletion.
Thus, the vitamin B6 metabolism appears to regulate stress
management in a rather general fashion. This is not surprising
given that PLP constitutes the prosthetic group of more than
4% of all enzymes, many of which can influence stress-relevant
metabolic circuitries such as those controlling the redox balance
(Percudani and Peracchi, 2003). These observations imply that
PN renders cancer cells more sensitive to chemical and physical
stress via a general, multipronged effect on intermediate metab-
olism rather than by targeting a single enzymatic activity.
Driven by our pre-clinical results, we quantified (by immuno-
histochemistry) the expression level of PDXK in specimens
from two independent series of patients with NSCLC. Reduced
PDXK expression negatively influenced disease-free and overall
survival in patients with NSCLC, irrespective of whether they
received adjuvant chemotherapy or not, de facto constituting
a prognostic biomarker. Intriguingly, circulating vitamin B6 levels
negatively correlate with the risk of developing clinically manifest
NSCLC (Johansson et al., 2010) and other highly prevalent
malignancies including ovarian (Harris et al., 2011) and colorectal
cancer (Larsson et al., 2010). Thus, pyridoxine, PDXK, and/or
perhaps hitherto unexplored PLP-dependent enzymatic activi-
tiesmay have a profound impact on cancer biology that warrants
further investigation.
In conclusion, this study outlines a systems biology strategy
for the identification of novel cell death regulators, leading to
the discovery of a biomarker for risk stratification in NSCLC. It
is our hope that these efforts as well as complementary
approaches undertaken by other laboratories will pave the way
to an ever more refined stratification of cancer patients and
Figure 6. Prognostic Value of PDXK in Patients with NSCLC
(A) Immunohistochemical detection of PDXK levels in biopsies from patients with NSCLC. Bars indicate picture scale. See also Figure S6.
(B and C) Kaplan-Meier curves for DFS and OS, in two distinct cohorts of 114 (B) and 218 (C) patients with NSCLC, upon stratification of patients according to
median PDXK expression. p values (log-rank test) are depicted. Please note that, in (B), information onDFSwas available for 111 patients only. See also Figure S7.hence to an increasingly sophisticated or ‘‘personalized’’ follow-
up, treatment and cure.
EXPERIMENTAL PROCEDURES
Unless otherwise specified, all experiments were performed in triplicate and
repeated at least twice. Data are reported as means ± SEM.
Transfections
The genome-wide siRNA library HumanWhole Genome siRNA Set Version 1.0
(QIAGEN, Hilden, Germany) was used in this study. The sequences of the
siRNAs selected for low-throughput validation analyses, as well as those of
other siRNAs that were employed in this study are reported in Table S2. To
avoid depleting the siRNA library of selected sequences, siRNAs for validation
experiments were purchased as custom molecules from Sigma-Aldrich
(St. Louis, Missouri, USA). For low-throughput experiments, (see below for
the transfection protocols employed in the siRNA screen), siRNA were trans-
fected in A549 cells with Oligofectamine reagent (Invitrogen, Carlsbad,
USA), following the manufacturer’s instructions. Transfection with a non-
targeting siRNA (siUNR) was employed as a negative control condition.
Forty-eight hours after transfection, siRNA-mediated target downregulation
was assessed by immunoblotting (see Supplemental Information).
Cytofluorometry
To measure apoptosis-related parameters, living cells were co-stained for
30 min at 37C with 40 nM 3,30dihexiloxalocarbocyanine iodide (DiOC6(3),
from Molecular Probes-Invitrogen, Eugene, Oregon, USA), which quantifies
the mitochondrial transmembrane potential (Dcm), plus 1 mg/ml propidium
iodide (PI), which only accumulates in cells with ruptured plasma membrane
(Galluzzi et al., 2007, 2008, 2009). For the quantification of intracellular reduced
glutathione (GSH), cells were labeled for 30min at 37Cwith 50 mMmonochlor-
obimane (MCB, fromMolecular Probes-Invitrogen). All cytofluorometric deter-
minations were carried out a FACSCalibur or a FACScan cytofluorometer (BD
Biosciences, San Jose, California, USA) equipped with a 70 mm nozzle.First line statistical analysis of cytofluorometric results was performed by
using the CellQuest software (BD Biosciences), by gating on the events
characterized by normal forward scatter and side scatter parameters.
Cytofluorometric data were further analyzed with Microsoft Excel (Microsoft
Co., Redmond, WA, USA) and statistical significance was assessed by means
of two-tailed Student’s t test (p < 0.05).
ImmunofluorescenceMicroscopy for the Detection of DNADamage-
Related Signaling
Immunofluorescence microscopy determinations of DNA damage-related
events were performed as previously described (Vitale et al., 2007, 2008).
Briefly, cells were fixed in 4% (w/v) paraformaldehyde in PBS, permeabilized
with 0.1% SDS and immunostained with antibodies recognizing phospho-
ATM(Ser1981) (mouse monoclonal IgG1k no. 05-740, Upstate, Billerica,
Massachusetts, USA) and phospho-H2AX(Ser139) (g-H2AX, rabbit antiserum
no. 4411, Trevigen, Gaithersburg, Maryland, USA). Slides were then incu-
bated with the appropriate Alexa Fluor 488 conjugates (Molecular Probes-In-
vitrogen) in the presence of 10 mM Hoechst 33342 (Molecular Probes-Invitro-
gen) for nuclear counterstaining. Fluorescence images were acquired using an
IRE2microscope equipped with a DC300F camera (both from Leica Microsys-
temsGmbH,Wetzlar, Germany). Image analysis was performedwith the open-
source software Image J (National Institutes of Health). The percentage of
phospho-ATM and g-H2AX positivity was assessed by scoring cells that ex-
hibited more than 5 and 10 very bright nuclear spots (DNA damage foci),
respectively.
Quantification of Intracellular B6 Vitamers
A549 cells were cultured in absence or the presence of 5 mM pyridoxine (PN),
pyridoxamine (PM) or pyridoxal-5-phosphate (PLP) for 24 or 48 hr, harvested,
washed once in cold PBS, and pelleted at 800 G for 10min. Supernatants were
discarded and pellets were dissolved in 500 ml of deionized H2O by vortexing
for 1 min followed by sonication for 10 min. Thereafter, lysates were centri-
fuged at 5,796 G for 10 min and 60 ml of the resulting supernatant were mixed
with an equal volume of trichloroacetic acid (TCA). Upon additionalCell Reports 2, 257–269, August 30, 2012 ª2012 The Authors 267
centrifugation (5,796 G, 10 min), 50 ml of sample were injected onto the chro-
matographic column and PLP, PN, PM and pyridoxal (PL) were measured by
liquid chromatographywith tandemmass spectrometry (LC-MS/MS), as previ-
ously described (Johansson et al., 2010; Midttun et al., 2009).
Metabolomic Profiling
The profiling of intracellular metabolites was performed on a RRLC 1260
system coupled to a Quadripole-Time of Flight (QTOF) 6520 mass spectrom-
eter (Agilent Technologies, Santa Clara, California, USA), equipped with an
electrospray source operating in positive ion and full scan mode from 100 to
1000 Da. The gas temperature was set to 250C with a gas flow of 8 l/min.
Capillary voltage was set to 4.0 kV, and the fragmentor to 100 V. Two reference
masses were used to maintain mass accuracy throughout the analysis:
121.050873 and 922.009798 Da. Samples (2 ml) were injected on a 150 3
2.1 mm, 3.5 mm Stable Bond AQ column with a 30 3 2.1 mm, 3.5 mm Eclipse
plus pre-column (Agilent Technologies). The gradient mobile phase consisted
of 0.2% (v/v) acetic acid in water (A) and 0.2% (v/v) acetic acid in methanol (B).
The initial composition of the mobile phase was 2% of B, followed by an
increase up to 95% of B, uniformly distributed across 15 min. The flow rate
was set to 0.3 ml/min. Data collection and analysis were performed with the
MassHunter software.
Mouse Strains
C57BL/6 (H-2b) and Swiss Nude mice were obtained from Janvier (Le Genest
St. Isle, France) and Charles River (Lille, France), respectively. Animals were
maintained in pathogen-free conditions, and all experiments were carried
out (upon approval by the local ethical committee, CEEA IRCIV / IGR n26,
registered with the French Ministry of Research) in compliance with Directive
EU 63/2010 and following the Federation of European Laboratory Animal
Science Association (FELASA) guidelines. Six- to 12-week-old mice were
used. During the experiments, animals were subjected to an artificial light cycle
(12 hr lights on, 12 hr lights off) and allowed food and drink ad libitum.
Tumor Graft Models
In one model, 5 3 105 Lewis lung carcinoma (LLC) cells were subcutaneously
grafted (in 100 ml sterile PBS) in immunocompetent (C57BL/6) mice. Alterna-
tively, human 5 3 106 NSCLC H460 cells were subcutaneously xenografted
(in 100 ml sterile PBS) in immunodeficient (Swiss nude) mice. For induction
models (LLC and H460 cells), when the tumor surface reached 25–40 mm2,
10–20 mice were assigned to one of four different treatment groups: group
1 = 100 ml intraperitoneal PBS; group 2 = 5 mg/kg intraperitoneal cisplatin
(CDDP) in 100 ml PBS; group 3 = 170 mg/kg intratumoral PN in 100 ml PBS;
group 4 = 5 mg/kg intraperitoneal CDDP in 100 ml PBS + 170 mg/Kg intratu-
moral PN in 100 ml PBS. For regression studies (LLC cells), tumors were al-
lowed to reach a surface of 75–100 mm2, then 10–20 mice were assigned to
one of four different treatment groups: group 1 = 100 ml intraperitoneal PBS;
group 2 = 25 mg/kg intraperitoneal CDDP in 100 ml PBS; group 3 = 170 mg/kg
intratumoral PN in 100 ml PBS; group 4 = 25 mg/kg intraperitoneal CDDP in
100 ml PBS + 170mg/kg intratumoral PN in 100 ml PBS. In all cases, treatments
were administered three times a week (days 1, 3, and 5; day 8 = day 1), tumor
size was routinely monitored bymeans of a standard caliper and tumor volume
was extrapolated as previously described (Streit et al., 1999). Animals bearing
tumors that exceeded 20%–25% of total body mass or that exhibited large
necrotic lesions were sacrificed. Statistical significance was evaluated by
two-way ANOVA.
Patients
Tumors resected from 114 patients with NSCLC from the Institut Mutualiste
Montsouris (Paris, France) were fixed in neutral buffered 10% formalin solution
and paraffin-embedded. Inclusion criteria were: (1) histologic diagnosis of
NSCLC, and (2) complete tumor resection. These biopsy specimens were
collected in the context of the CHEMORES initiative (an EU funded research
collaboration aimed at improving cancer treatment by obtaining increased
knowledge on mechanisms of chemotherapy resistance) between 2002 and
2006. Tumor biopsies from 218 patients with NSCLCwho never received adju-
vant chemotherapy were collected at the MD Anderson Cancer Center (Hous-
ton, Texas, USA) in the form of tissuemicroarrays. An informedwritten consent268 Cell Reports 2, 257–269, August 30, 2012 ª2012 The Authorswas always obtained from patients, according to the local ethical committee.
The main patients’ characteristics (i.e., age, sex, tumor histology, follow-up,
administration of adjuvant chemotherapy, and other) are summarized in
Table 1.
The full set of experimental procedures and statistical methods can be found
online as Supplemental Information.
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